权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort)

针对 HPV 相关非艾滋病定义癌症的新型靶向疗法（生物样本/生物队列）

基本信息

批准号：
10620083
负责人：
STEVEN Terry ROSEN
金额：
$ 25万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10620083
关键词：
AIDS related cancer Blood COVID-19 vaccine Cell Death Cell Line Data Dependence Development Engineering Etiology Gene Delivery Gene-Modified Genome Genomics Goals Grant Growth HIV HPV-High Risk Head Cancer Head and Neck Cancer Head and neck structure Human Papilloma Virus-Related Malignant Neoplasm Human Papillomavirus Human papillomavirus 16 Individual Infection Intervention Maintenance Malignant Neoplasms Malignant neoplasm of anus Malignant neoplasm of cervix uteri Methods Mission Modeling Neck Oncogenes Oncogenic Viruses Oncornaviruses Patient Representative Persons Promoter Regions Proteins Public Health RNA delivery Repressor Proteins Research System Testing Therapeutic Therapeutic Intervention United States National Institutes of Health Viral Viral Genes Viral Oncogene Vulnerable Populations Work Zinc Fingers anti-cancer carcinogenicity co-infection combat high risk human papilloma virus oncogene in vivo in vivo Model innovation leukemia lipid nanoparticle mouse model nanoparticle delivery new therapeutic target novel novel therapeutic intervention oncogene addiction patient derived xenograft model success targeted treatment therapeutic RNA therapeutic development therapeutic gene therapeutic target tumor

项目摘要

Project Summary/Abstract Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort) The incidents of non-AIDS-defining cancers (NADC) are increasing in HIV-infected individuals (HIVIIs), urging the development of therapeutic interventions. Many HIV-associated cancers are a result of co-infections with oncogenic viruses, and the high-risk human papillomavirus (HPV) is prevalent in the development of several NADCs, including head-and-neck (HNC) and anal cancers. Importantly, the HPV viral oncogenes are involved in the transformation and maintenance of these cancers and are considered unique targets in HPV-associated malignancies. Often considered `undruggable', these viral genes are susceptible to targeted gene therapeutic strategies and we have developed a novel, potent zinc finger protein (ZFP) that can strongly repress viral oncogenes to elicit anti-cancer effects; a promising approach to HPV-associated NADCs. Furthermore, lipid nanoparticles (LNPs) are a therapeutically relevant non-viral delivery system, which we have used previously for in vivo delivery of RNA-based therapeutics. Importantly, even though the HPV oncogenes represent viable therapeutic targets, there are no studies investigating the potential anti-proliferative effect of targeting the viral oncogenes in HPV-associated tumors from HIVIIs in vivo. Our long-term goal is to develop innovative interventions for the treatment of virally driven cancers emerging in HIVIIs, with the objective of this project to use LNP-delivered ZFP repressors to inactive HPV oncogenes in NADCs. Guided by our strong preliminary data and expertise using targeted repressors and nanoparticle delivery systems, we propose two complementary but distinct objectives, 1) the characterization of novel, potent ZFP repressors for anti-proliferative effects in HPV- associated cell line models relevant to NADCs, and 2) to assess LNP-delivered anti-HPV effectors to inhibit HPV-associated HNCs from HIVIIs in a patient-derived xenograft (PDX) murine model. Collectively, this work will be impactful by developing an innovative targeted repressor to inhibit HPV-associated NADCs, offering a novel intervention to malignancies increasing in HIVIIs.

项目总结/文摘